PD-L1 Expression by Tumor-Infiltrating Cells Associated With Activity of Anti–PD-L1 Antibody in Multiple Cancer Types

Get Permission

Programmed cell death protein ligand 1 (PD-L1) interferes with anticancer immune response by binding programmed PD-1 and B7.1 (CD80), negative regulators of T-cell activation. In a study reported in Nature, Herbst and colleagues showed that treatment with an anti–PD-L1 antibody (MPDL3280A) produced responses across multiple cancer types in patients with tumors expressing high levels of PD-L1 and particularly when PD-L1 was expressed by tumor-infiltrating immune cells. Responses were also associated with T-helper type 1 gene expression, CTLA-4 (cytotoxic T-lymphocyte–associated protein-4) expression, and absence of fractalkine (CX3CL1) in baseline tumor samples.

The investigators concluded: “[T]hese data suggest that MPDL3280A is most effective in patients in which preexisting immunity is suppressed by PD-L1 and is reinvigorated on antibody treatment.”

More detailed information about this study may be found on page 48 in this issue of The ASCO Post. ■

Herbst RS, et al: Nature 515:563-567, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.